新型运动量表用于评估异常蛋白病患者的三年研究
该研究基于187例异常蛋白病患者3年的纵向功能评估数据,采用Rasch分析开发了适用于可行走和不可行走患者的NSAD运动量表,并用广义估计方程评估患者因素对结局轨迹的影响。结果显示NSAD能检测到1年内的显著临床进展,症状出现后前10年功能下降最陡,发病年龄较轻者下降更快(p=0.04)。
要点
- NSAD是首个经验证的肢带型肌营养不良症特异性运动性能量表。
- NSAD可检测异常蛋白病1年内的显著功能变化。
- 症状出现后前10年功能下降最陡,发病年龄较轻者下降更快。
核心结论
- NSAD是首个经验证的肢带型肌营养不良症特异性运动性能量表,适用于临床实践和临床试验。
研究设计与样本
- 研究收集了187例异常蛋白病患者为期3年的纵向功能评估数据。
- 采用Rasch分析开发NSAD量表,并用广义估计方程评估患者因素对结局轨迹的影响。
主要发现
- NSAD能检测到1年内临床进展的显著变化。
- 功能下降最陡的时期为症状出现后前10年。
- 发病年龄较轻的患者功能下降更快(p=0.04)。
- 基线时处于症状出现后3至8年的患者在研究期间功能恶化最快。
临床怎么用
- NSAD可用于异常蛋白病患者的临床实践和临床试验中的运动功能评估。
- 纵向分析有助于识别与更大功能下降相关的患者因素,为临床试验准备提供参考。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Dysferlinopathy is a muscular dystrophy with a highly variable clinical presentation and currently unpredictable progression. This variability and unpredictability presents difficulties for prognostication and clinical trial design. The Jain Clinical Outcomes Study of Dysferlinopathy aims to establish the validity of the North Star Assessment for Limb Girdle Type Muscular Dystrophies (NSAD) scale and identify factors that influence the rate of disease progression using NSAD. METHODS: We collected a longitudinal series of functional assessments from 187 patients with dysferlinopathy over 3 years. Rasch analysis was used to develop the NSAD, a motor performance scale suitable for ambulant and nonambulant patients. Generalized estimating equations were used to evaluate the impact of patient factors on outcome trajectories. RESULTS: The NSAD detected significant change in clinical progression over 1 year. The steepest functional decline occurred during the first 10 years after symptom onset, with more rapid decline noted in patients who developed symptoms at a younger age (p = 0.04). The most rapidly deteriorating group over the study was patients 3 to 8 years post symptom onset at baseline. INTERPRETATION: The NSAD is the first validated limb girdle specific scale of motor performance, suitable for use in clinical practice and clinical trials. Longitudinal analysis showed it may be possible to identify patient factors associated with greater functional decline both across the disease course and in the short-term for clinical trial preparation. Through further work and validation in this cohort, we anticipate that a disease model incorporating functional performance will allow for more accurate prognosis for patients with dysferlinopathy. ANN NEUROL 2021;89:967-978.
引用
- Jacobs MB, James MK, Lowes LP, et al. Assessing Dysferlinopathy Patients Over Three Years With a New Motor Scale. Ann Neurol. 2021. PMID: 33576057. doi:10.1002/ana.26044
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。